This post was originally published on this site Janssen has asked the U.S. Food and Drug Administration (FDA) to approve a new subcutaneous (under-the-skin) formulation of Darzalex (daratumumab) as a faster and easier treatment for people with multiple myeloma. Currently, Darzalex is approved as an intravenous infusion into a vein that takes several hours. The biologics license…
About Cancer
Cancer, also called malignancy, is an abnormal growth of cells with the potential to invade or spread to surrounding tissues and structures found within the body. There are more than 100 types of cancer. A few examples include breast cancer, skin cancer, lung cancer, colon cancer, prostate cancer, and lymphoma. According to the American Cancer Society, 4 out of 10 people will be diagnosed with some form of cancer in their lifetime. Cancer prevalence has given rise to multiple medical specialties focused on symptom management and disease management. Current treatment options depending on the form of cancer include chemotherapy, radiation, blood or bone marrow transfusions, and/or surgery. Lifetime prognosis of cancer mortality is dependent on the type of cancer and is heavily conditional to early detection.
Conditions
Cancer News
Transgene Completes Enrollment for Phase 2 Trial of Triple Combo NSCLC Therapy
This post was originally published on this site Transgene has completed patient enrollment for its Phase 2 trial evaluating the cancer vaccine TG4010 in combination with Opdivo (nivolumab) and chemotherapy as a first-line treatment for advanced non-squamous non-small cell lung cancer (NSCLC) with low or no expression of PD-L1. The first results regarding the trial’s…
Trilaciclib-Chemo Combo Extends Lives of Triple-negative Breast Cancer Patients, Preliminary Phase 2 Findings Show
This post was originally published on this site Trilaciclib, a treatment that protects the bone marrow from the damaging effects of chemotherapy, significantly extends the lives of women with metastatic triple-negative breast cancer receiving a chemotherapy regimen of gemcitabine and carboplatin, G1 Therapeutics announced. Chemotherapy kills tumor cells that divide rapidly. However, a major side…
FDA Grants Fast Track Status to Investigational Compound CLR 131 for DLBCL
This post was originally published on this site Cellectar Biosciences’ investigational radiotherapeutic compound, CLR 131, has received fast track designation by the U.S. Food and Drug Administration (FDA) for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The designation will support and help expedite CLR 131’s clinical development, as well as its…
FDA Will Review Application Seeking Expansion of Keytruda’s Dosing Schedule
This post was originally published on this site The U.S. Food and Drug Administration (FDA) has accepted for review six supplemental biologics license applications (sBLAs) seeking to expand the dosing schedule of Keytruda (pembrolizumab) so the medication can be administered every six weeks. Keytruda is a checkpoint blockade immunotherapy developed by Merck (known as MSD…
What Cancer Taught Me About Being a Mom
This post was originally published on this site I dated a guy in college who described the time he saw a nasty brown stain on his shower floor. When he called his mother, she explained that he would need to clean it with cleanser and a sponge. All his life he assumed that the shower…
Veyonda-LuPSMA Radiotherapy Safe, Well-tolerated in Advanced PC, Early Trial Results Show
This post was originally published on this site A combination of Noxopharm’s radiation sensitizer Veyonda (idronoxil) and 177LuPSMA-617 — a kind of targeted radiation therapy — is safe and well-tolerated, and appears to have a high efficacy in men with metastatic castration-resistant prostate cancer (mCRPC), preliminary results from an ongoing Phase 1/2 trial show. The…
Scientists Discover Enzyme with Key Role in Aggressive Ovarian Cancers
This post was originally published on this site Scientists discovered a metabolic enzyme that adds methyl groups to other molecules, called nicotinamide N-methyltransferase, that plays an important role in the progression of high-grade serous carcinoma, the most deadly form of ovarian cancer. The findings of the study, “Proteomics reveals NNMT as a master metabolic regulator…
Specific DNA Rearrangement Predicts Treatment Resistance, Poor Outcomes in Multiple Myeloma, Study Suggests
This post was originally published on this site A genomic rearrangement involving the immunoglobulin lambda (IgL) gene is predictive of resistance to immunomodulatory agents and poor outcomes among multiple myeloma patients, a new study suggests. Testing for this rearrangement of chromosomes may help better stratify patients according to their risk of disease progression and tailor…
Blood Cell Count Abnormalities Might Indicate Bone Marrow Involvement in Sarcoidosis, Report Suggests
This post was originally published on this site Alterations in the blood cell count of people with sarcoidosis might indicate that the disease has invaded the bone marrow, a case report suggests. Doctors should therefore consider this clinical sign to aid in early diagnosis and avoid further complications. The study, “Bone marrow involvement in sarcoidosis:…
$20M Gift to Dana-Farber Will Establish Fund for Metastatic Breast Cancer Research
This post was originally published on this site The Dana-Farber Cancer Institute will get $20 million to create the Saverin Breast Cancer Research Fund aimed at extending the lives of metastatic breast cancer patients. The gift from the “Saverin Family” is the largest individual gift for breast cancer research in the institute’s history. No further…
MDNA55-Interferons Combo Kills Cancer Cells, Extends Lifespan of Mice with Ovarian Cancer, Study Reports
This post was originally published on this site Combining the experimental therapy MDNA55 with anti-cancer interferons (IFNs) can effectively kill cancer cells and extend the survival of mice with metastatic ovarian cancer, new research results show. The study, “Combination immunotherapy with IL-4- Pseudomonas exotoxin and IFN-α and IFN-γ mediate antitumor effects in vitro and in a mouse model…